Joyce F Liu

Trials

Studies that name Joyce F Liu as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:59 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT05691504 · Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

  National Cancer Institute (NCI) · active not recruiting · Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma · principal investigator
• Ph3
  NCT02446600 · Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

  National Cancer Institute (NCI) · active not recruiting · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma · principal investigator
• Ph2
  NCT02345265 · Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer

  National Cancer Institute (NCI) · active not recruiting · Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma · principal investigator
• Ph1/Ph2
  NCT01116648 · Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

  National Cancer Institute (NCI) · active not recruiting · Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• PDX Modeling Core
  P01CA269021 · NCI · DANA-FARBER CANCER INST · fiscal years 2024 to 2026 · $433,259 awarded in 2026
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
  UM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2019 to 2026
  Named on NCT05691504, NCT02345265, NCT01116648
• NRG Oncology Network Group Operations Center
  U10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Quynh-Thu Xuan Le, ROBERT S. MANNEL, NORMAN WOLMARK · fiscal years 2019 to 2026
  Named on NCT02446600
• North American Star Consortium
  UM1CA186644 · NCI · UNIVERSITY HEALTH NETWORK · PI Philippe Bedard, Kevin D Courtney, Steven Grant, Salma Jabbour, Jeffrey Lancet, Devalingam Mahalingam, Lillian L Siu, JONATHAN C TRENT · fiscal years 2019 to 2026
  Named on NCT02345265
• NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 Emphasis
  UM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2019
  Named on NCT02345265
• NCI ETCTN Pittsburgh Cancer Consortium (PCC)
  UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2019 to 2026
  Named on NCT02345265
• The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
  UM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2019 to 2026
  Named on NCT02345265
• Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
  UM1CA186704 · NCI · DUKE UNIVERSITY · PI JAMES L. ABBRUZZESE, ELIZABETH CLAIRE DEES, Andrea Wang-Gillam · fiscal years 2019
  Named on NCT02345265
• The Ohio State University as a Lead Academic Organization (LAO) for the Experimental Therapeutics Clinical Trials Network
  UM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON, Narendranath Epperla · fiscal years 2019 to 2026
  Named on NCT02345265
• Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics
  UM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2019
  Named on NCT02345265
• Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
  UM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2019 to 2026
  Named on NCT02345265
• Administrative Core
  P30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2019 to 2026
  Named on NCT01116648
• U01CA062490
  RePORTER returned no project for this number; it is shown as the registry gives it.
  Named on NCT01116648